COLL News and Press, Collegium Pharmaceutical Inc. From 11/03/22

– Generated Record Net Revenue of $127.0 Million – – Completed Xtampza ® ER Contract Renegotiations, Confirmed Xtampza ER Gross-To-Net Will be Less Than 65% Beginning January 2023 – – Returned $10M in Capital to Shareholder...

STOUGHTON, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that it will report third quarter 2022 financial results after the market closes on Thursday, November 3, 2022...

STOUGHTON, Mass., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that 11 poster presentations highlighting data regarding its product portfolio will be presented at the Annual PAIN...

H.C. Wainwright analyst Oren Livnat downgraded Collegium Pharmaceutical ( COLL ) to Neutral from Buy without a price target. The company's prescription trajectories are "flat until proven otherwise," and consensus earnings estimates look too high, Livnat tells investors. The a...

Collegium Pharmaceutical, Inc. (COLL) Q2 2022 Results Conference Call August 04, 2022 4:30 PM ET Company Participants Alex Dasalla - Head, IR Joseph Ciaffoni - CEO Colleen Tupper - CFO Scott Dreyer - CCO Conference Call Participants Greg Fraser - ...

Collegium Pharmaceutical press release ( NASDAQ: COLL ): Q2 GAAP EPS of -$0.15 misses by $0.21 . Revenue of $123.55M (+49.0% Y/Y) beats by $2.33M . Adjusted EBITDA for the 2022 Quarter was $71.2 million, compared to $40.1 million for the 2021 Quarter The Co...

– Generated Record Net Revenue of $123.5 Million – – BDSI Integration Complete; On Track to Exceed Targeted Run Rate Synergies of at Least $75 Million – – Raises Full Year Adjusted EBITDA Guidance – – Conference Ca...

STOUGHTON, Mass., July 21, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that it will report second quarter 2022 financial results after the market closes on Thursday, August 4, 2022. Foll...

Shares of pain management drug concern Collegium Pharmaceutical have fallen over 40% as the biotech selloff, negative attitudes towards opiates, and patent cliffs have taken a toll. The company's recent purchase of BioDelivery Sciences provides it with complementary suite of assets, a...

Pharmaceuticals and biotechnology are cheap relative to 11-year valuation averages. Life science tools and healthcare equipment are overvalued. IXJ: a global alternative to XLV. 10 stocks cheaper than their peers in May. For further details see: IXJ: Healthcare Dashb...